Louisville, Kentucky-based Humana Inc. (HUM) provides medical and specialty insurance products in the United States. The company has a market cap of $42 billion and operates in two segments, Insurance and CenterWell, and offers individual Medicare Advantage products, including health insurance benefits, wellness programs, chronic care management, and care coordination.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” HUM fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the healthcare plans industry.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
HUM stock reached its 52-week high of $351.88 on June 5, and has slipped marginally from that peak. The stock has grown 93.7% over the past three months, rallying the Nasdaq Composite ($NASX), which rose 13% over the same period.
www.barchart.com Over the longer term, the scenario remains the same. HUM is up nearly 54.1% over the past 52 weeks, outperforming NASX's 33.2% return over the same period.
HUM has been trading above its 200-day moving average since May and also above its 50-day moving average since April.
www.barchart.com On Apr. 29, HUM stock rose 5.8% following the release of its Q1 2026 earnings. The company’s revenue for the quarter amounted to $39.7 billion, surpassing the Street’s estimates. Moreover, its adjusted EPS came in at $10.31, also coming in on top of Wall Street’s estimates.
When stacked against its closest peer in the healthcare plans industry, The Cigna Group (CI) shares have declined 6.9% over the past 52 weeks, underperforming HUM stock.
Wall Street’s view of HUM stock is moderately optimistic. Among the 27 analysts covering the stock, the overall consensus rating is “Moderate Buy.” Its mean price target of $288.22 is below current levels, but its Street-high target of $441 indicates 26% upside potential.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Using SPY Put Options For Portfolio Protection Stocks Set to Open Higher Despite Israel-Iran Escalation, U.S. Inflation Data and SpaceX IPO Awaited Netflix Rolls Out Generative AI Tools to Fix the Content Overload Problem It Created Netflix’s Underperforming Stock Needs a New Story. It Can’t Be AI.